CHANGES IN URINARY THROMBOXANE LEVEL IN MAN DURING CARDIOPULMONARY BYPASS - EFFECT OF THROMBOXANE ON RENAL TUBULES

ONO-3708, a thromboxane A2 (TXA2) antagonist, was administered at a dose of 2 μg/kg/min by a double blind method as compared with inactive placebo during cardiopulmonary bypass (CPB) procedure to study the changes of thromboxane B2 (TXB2) levels in plasma and urine and N-acetyl-glucosaminidase (NAG) level in urine. TXB2 levels in plasma and urine increased significantly (P < 0.01) during CPB in the patients given ONO-3708 (ONO-3708 group) and in those given placebo (placebo group). The plasma TXB2 level as expected from the urinary TXB2 level was higher than the measure plasma TXB2 level showing increases in TXB2 originating from the kidney. The urinary NAG level, increased significantly (P < 0.01) during CPB the NAG level in ONO-3708 group was significantly low as compared to placebo group. © 1990.